year 14, Issue 2 (March - April 2020)
Iran J Med Microbiol 2020, 14(2): 162-181 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Darvishi M, Forootan M, Nazer M R, Karimi E, Noori M. Nosocomial Infections, Challenges and Threats: A Review Article. Iran J Med Microbiol 2020; 14 (2) :162-181
URL: http://ijmm.ir/article-1-939-en.html
URL: http://ijmm.ir/article-1-939-en.html
1- Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Faculty of Aerospace and Subaquatic Medicine, AJA University of Medical Sciences, Tehran, Iran
2- Department of Gastroenterology, Gastrointestinal and Liver Diseases Research Center (RCGLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Department of Infectious Diseases, Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
4- Department of Emergency Medicine, Besat Hospital, AJA University of Medical Sciences, Tehran, Iran
5- Infectious Diseases and Tropical Medicine Research Center (IDTMRC), AJA University of Medical Sciences, Tehran, Iran , dr.majid.nouri@gmail.com
2- Department of Gastroenterology, Gastrointestinal and Liver Diseases Research Center (RCGLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Department of Infectious Diseases, Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
4- Department of Emergency Medicine, Besat Hospital, AJA University of Medical Sciences, Tehran, Iran
5- Infectious Diseases and Tropical Medicine Research Center (IDTMRC), AJA University of Medical Sciences, Tehran, Iran , dr.majid.nouri@gmail.com
Abstract: (5785 Views)
Nosocomial infections or healthcare associated infections occur in patients under medical care. Infections acquired in hospitals have existed since the very inception of hospitals themselves, and continue to be an important health problem even in the modern era of antibiotics. Today, they result in high morbidity and mortality, extended hospitalization, greater use of antibiotics, and increased costs. The overuse and inappropriate consumption and application of antibiotics have driven the rapid emergence of multidrug-resistant drugs (MDR) pathogens. Combating MDRs which cause serious life threatening nosocomial infections and appear to be biologically compatible with their environment, are difficult to manage due to the limited treatment options. The worldwide emergence of multidrug resistance (MDR) among Gram negative and Gram-positive bacteria has caused a great threat to fight the bacterial pathogens. It is clear that in the lack of a timely, efficient solution the challenge of antibiotic resistance becomes alarming and will cause a great challenge in the forthcoming years. In this review article we will discuss the most important MDR nosocomial infection agents, including Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa as major threats throughout the world.
Type of Study: Review Article |
Subject:
Nosocomial infections
Received: 2019/05/26 | Accepted: 2020/04/14 | ePublished: 2020/05/30
Received: 2019/05/26 | Accepted: 2020/04/14 | ePublished: 2020/05/30
References
1. Curtis A, Moore Z, Patton D, O'Connor T, Nugent L. Does using a cellular mobile phone increase the risk of nosocomial infections in the Neonatal Intensive Care Unit: A systematic review. J Neonat Nurs. 2018 Oct 1;24(5):247-52. [DOI:10.1016/j.jnn.2018.05.008]
2. Hormozi SF, Saeedi AA, Aminianfar M, Alishah MS, Darvishi M. Studying the frequency of nosocomial infection and its relative factors in the intensive care unit of hospitals based upon NNI system. Eurasia J Analytic Chemist. 2018 Jan 1;13(3):em16. [DOI:10.29333/ejac/85014]
3. Reid R, Sheehy C, Jabbour L. Risk factors and interventions against nosocomial infections across multiple African countries: a systematic review. CPQ Medicine. 2018;2(2):1-2.
4. Darvishi M. Virulence factors profile and antimicrobial resistance of Acinetobacter baumannii strains isolated from various infections recovered from immunosuppressive patients. Biomed Pharmacol J. 2016 Dec 22;9(3):1057-62. [DOI:10.13005/bpj/1048]
5. Nazir A, Kadri SM. An overview of hospital acquired infections and the role of the microbiology laboratory. Int J Res Med Sci. 2014 Feb;2(1):21-7. [DOI:10.5455/2320-6012.ijrms20140205]
6. Debnath T, Bhowmik S, Islam T, Hassan Chowdhury MM. Presence of Multidrug-Resistant Bacteria on Mobile Phones of Healthcare Workers Accelerates the Spread of Nosocomial Infection and Regarded as a Threat to Public Health in Bangladesh. J Microsc Ultrastruct. 2018;6(3):165-9. [DOI:10.4103/JMAU.JMAU_30_18] [PMID] [PMCID]
7. World Health Organization. Prevention of hospital-acquired infections: a practical guide (No. WHO/CDS/CSR/EPH/2002.12). Geneva, Switzerland: World Health Organization. 2002.
8. Samuel SO, Kayode OO, Musa OI, Nwigwe GC, Aboderin AO, Salami TAT, et al. Nosocomial infections and the challenges of control in developing countries. AFR J CLN EXPER MICROBIOL. 2010;11(2):102-10. [DOI:10.4314/ajcem.v11i2.53916]
9. Kliegman RM, Behrman RE, Jenson HB, Stanton BM. Nelson textbook of pediatrics e-book. Elsevier Health Sciences; 2007 Aug 15.
10. Darvishpoor K, Rezaei Manesh MR. Prevalence of nosocomial infections and microbial causes in Torbat heydariyeh 9dey educational and clinical hospital in 2012 and 2013.Iran J Med Microbiol. 2016; 10 (1) :93-6.
11. Weber S, Hogardt M, Reinheimer C, Wichelhaus TA, Kempf VAJ, Kessel J, et al. Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases. Ann Hematol. 2019;98(3):763-73. [DOI:10.1007/s00277-019-03607-z] [PMID]
12. Medina E, Pieper DH. Tackling threats and future problems of multidrug-resistant bacteria. InHow to Overcome the Antibiotic Crisis 2016 (pp. 3-33). Springer, Cham. [DOI:10.1007/82_2016_492] [PMID]
13. Bereket W, Hemalatha K, Getenet B, Wondwossen T, Solomon A, Zeynudin A, Kannan S. Update on bacterial nosocomial infections. Eur Rev Med Pharmacol Sci. 2012 Aug 1;16(8):1039-44.
14. Hormozi SF, Vasei N, Aminianfar M, Darvishi M, Saeedi AA. Antibiotic resistance in patients suffering from nosocomial infections in Besat Hospital. Europ J Translation Myol. 2018 Jul 10;28(3). [DOI:10.4081/ejtm.2018.7594] [PMID] [PMCID]
15. Farzianpour F, Bakhtiari A, Mosavee SH, Akbarzadeh A. The most important species of nosocomial infection and the most important wards susceptible to nosocomial infection. Iran J Public Health. 2014:1016-7.
16. Falahi J, Khaledi A, Alikhani MY, Taghipour A, Amel JS, Honarmand M, et al. Prevalence of Nosocomial Infection in Different Wards of Ghaem Hospital, Mashhad. Avicenna J Clin Microbiol Infect. 2017;4(2):e40297. [DOI:10.5812/ajcmi.40297]
17. De Kraker ME, Davey PG, Grundmann H; BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8(10):e1001104. [DOI:10.1371/journal.pmed.1001104] [PMID] [PMCID]
18. Larypoor M, Frsad S. Evaluation of nosocomial infections in one of hospitals of Qom. Iran J Med Microbiol. 2011; 5 (3) :7-17
19. Wright SA, Bieluch VM. Selected nosocomial viral infections. Heart & lung: the journal of critical care. 1993;22(2):183-7.
20. Rubin LG, Kohn N, Nullet S, Hill M. Reduction in rate of nosocomial respiratory virus infections in a children's hospital associated with enhanced isolation precautions. Infect Control Hosp Epidemiol. 2018;39(2):152-6. [DOI:10.1017/ice.2017.282] [PMID]
21. Cavalheiro M, Teixeira MC. Candida Biofilms: Threats, Challenges, and Promising Strategies. Front Med (Lausanne). 2018;5:28. [DOI:10.3389/fmed.2018.00028] [PMID] [PMCID]
22. Morens DM, Fauci AS. Emerging infectious diseases: threats to human health and global stability. PLoS pathogens 2013;9(7):e1003467. [DOI:10.1371/journal.ppat.1003467] [PMID] [PMCID]
23. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P.T. 2015;40(4),277-83.
24. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization, Geneva, Switzerland. 2017.
25. Tatarelli P, Mikulska M. Multidrug-resistant bacteria in hematology patients: emerging threats. Future microbiol. 2016;11(6):767-80. [DOI:10.2217/fmb-2015-0014] [PMID]
26. Garoy EY, Gebreab YB, Achila OO, Tekeste DG, Kesete R, Ghirmay R, et al. Methicillin-Resistant Staphylococcus aureus (MRSA): Prevalence and Antimicrobial Sensitivity Pattern among Patients-A Multicenter Study in Asmara, Eritrea. Can J Infect Dis Med Microbiol. 2019;2019:8321834. [DOI:10.1155/2019/8321834] [PMID] [PMCID]
27. Nagendra Prasad HS, Karthik CS, Manukumar HM, Mallesha L, Mallu P. New approach to address antibiotic resistance: Miss loading of functional membrane microdomains (FMM) of methicillin-resistant Staphylococcus aureus (MRSA). Microb Pathog. 2019;127:106-15. [DOI:10.1016/j.micpath.2018.11.038] [PMID]
28. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005;5(5):275-86. [DOI:10.1016/S1473-3099(05)70112-2]
29. Islam T, Kubra K, Hassan Chowdhury MM. Prevalence of Methicillin-Resistant Staphylococcus aureus in Hospitals in Chittagong, Bangladesh: A Threat of Nosocomial Infection. J Microsc Ultrastruct. 2018;6(4):188-91. [DOI:10.4103/JMAU.JMAU_30_18] [PMID] [PMCID]
30. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13(12):1840-6. [DOI:10.3201/eid1312.070629] [PMID] [PMCID]
31. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46 Suppl 5(Suppl 5):S350-S359. [DOI:10.1086/533591] [PMID] [PMCID]
32. Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018;7:1. [DOI:10.1186/s13756-017-0291-z] [PMID] [PMCID]
33. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be?. Cmaj. 2009;180(4):408-15. [DOI:10.1503/cmaj.080239] [PMID] [PMCID]
34. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed. 2015;5(7):509-14. [DOI:10.1016/j.apjtb.2015.05.001]
35. Yang J, Yuan Y, Tang M, Liu L, Yang K, Liu J. Phenotypic and genetic characteristics of vancomycin-resistant Enterococcus faecium. Microb Pathog. 2019;128:131-5. [DOI:10.1016/j.micpath.2018.12.046] [PMID]
36. Jackson SS, Harris AD, Magder LS, Stafford KA, Johnson JK, Miller LG, et al. Bacterial burden is associated with increased transmission to health care workers from patients colonized with vancomycin-resistant Enterococcus. Am J Infect Control. 2019;47(1):13-7. [DOI:10.1016/j.ajic.2018.07.011] [PMID] [PMCID]
37. Hammerum AM, Baig S, Kamel Y, Roer L, Pinholt M, Gumpert H, et al. Emergence of vanA Enterococcus faecium in Denmark, 2005-15. J Antimicrob Chemother. 2017;72(8):2184-90. [DOI:10.1093/jac/dkx138] [PMID]
38. Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B, Leclercq R, et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother. 2011;66(4):713-21. [DOI:10.1093/jac/dkq524] [PMID]
39. Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany - 10 years of surveillance. Antimicrob Resist Infect Control. 2018;7:54. [DOI:10.1186/s13756-018-0353-x] [PMID] [PMCID]
40. Buetti N, Wassilew N, Rion V, Senn L, Gardiol C, Widmer A, et al. Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey. Antimicrob Resist Infect Control. 2019;8(1):16. [DOI:10.1186/s13756-019-0466-x] [PMID] [PMCID]
41. Ostria-Hernandez ML, Juárez-de la Rosa KC, Arzate-Barbosa P, Lara-Hernández A, Sakai F, Antonio Ibarra J, et al. Nosocomial, Multidrug-Resistant Klebsiella pneumoniae Strains Isolated from Mexico City Produce Robust Biofilms on Abiotic Surfaces but Not on Human Lung Cells. Microb Drug Resist. 2018;24(4):422-33. [DOI:10.1089/mdr.2017.0073] [PMID] [PMCID]
42. Azimi, Leila, et al. "Multi-drug resistant Pseudomonas aeruginosa and Klebsiella pneumoniae circulation in a burn hospital, Tehran, Iran." GMS hygiene and infection control. (2019). 14.
43. Hashemizadeh, Zahra, et al. "Characterization of SCCmec, spa types and Multi Drug Resistant of methicillin-resistant Staphylococcus aureus isolates among inpatients and outpatients in a referral hospital in Shiraz, Iran." BMC research notes 12.1 (2019): 614. [DOI:10.1186/s13104-019-4627-z] [PMID] [PMCID]
44. Ahmadi, Elham, et al. "Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus nasal carriage in the West of Iran: a population-based cross-sectional study." BMC infectious diseases 19.1 (2019): 899. [DOI:10.1186/s12879-019-4567-1] [PMID] [PMCID]
45. Bispo, Paulo JM, et al. "The Challenge of Antibiotic Resistance in Corneal Infection." Foundations of Corneal Disease. Springer, Cham, 2020. 277-88. [DOI:10.1007/978-3-030-25335-6_23]
46. Fallah, Fatemeh, Soha Parhiz, and Leila Azimi. "Distribution and antibiotic resistance pattern of bacteria isolated from patients with community-acquired urinary tract infections in Iran: a cross-sectional study." International Journal of Health Studies. (2019). 4.2. 27-36.
47. Pormohammad, Ali, et al. "Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis." Microbial pathogenesis 139 (2020): 103887. [DOI:10.1016/j.micpath.2019.103887] [PMID]
48. Oikonomou, O., et al. "Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data." BMC infectious diseases 15.1 (2015): 559. [DOI:10.1186/s12879-015-1297-x] [PMID] [PMCID]
49. Junnila Jenna,Hirvioja Tiina, Ritana Esa, Auranen, Kari et al, Changing epidemiology of methicillin-resistant Staphylococcus aureus in a low endemicity area-new challenges for MRSA control. Eur J Clin Microbiol Infect Dis. 2020.4(5).352-9. [DOI:10.1007/s10096-020-03824-9] [PMID]
50. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Emerging infections program healthcare-associated infections and antimicrobial use prevalence survey team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-208. [DOI:10.1056/NEJMoa1306801] [PMID] [PMCID]
51. Yasin F, Assad S, Talpur AS, Zahid M, Malik SA. Combination Therapy for Multidrug-Resistant Klebsiella Pneumoniae Urinary Tract Infection. Cureus. 2017;9(7):e1503. [DOI:10.7759/cureus.1503]
52. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study--authors' responseJ Antimicrob Chemother. 2015;70(7):2133-43. [DOI:10.1093/jac/dkv200] [PMID]
53. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. [DOI:10.1186/s12941-017-0191-3] [PMID] [PMCID]
54. Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16(10):749-61. [DOI:10.1080/14787210.2018.1522249] [PMID]
55. Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Evolution and epidemiology of multidrug-resistant Klebsiella pneumoniae in the United Kingdom and Ireland. MBio. 2017;8(1). pii: e01976-16. [DOI:10.1128/mBio.01976-16] [PMID] [PMCID]
56. Sikarwar AS, Batra HV. Challenge to healthcare: Multidrug resistance in Klebsiella pneumoniae. In 2011 International Conference on Food Engineering and Biotechnology IPCBEE. 2011;9:130-4. [DOI:10.7763/IJCEA.2011.V2.89]
57. Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 2019;32(1):69-76. [DOI:10.1097/QCO.0000000000000518] [PMID]
58. Richet H, Fournier PE. Nosocomial infections caused by Acinetobacter baumannii a major threat worldwide. Infect Control Hosp Epidemiol. 2006;27(7):645-6. [DOI:10.1086/505900] [PMID]
59. Almaghrabi MK, Joseph MRP, Assiry MM, Hamid ME. Multidrug-Resistant Acinetobacter baumannii: An Emerging Health Threat in Aseer Region, Kingdom of Saudi Arabia. Can J Infect Dis Med Microbiol. 2018;2018:9182747. [DOI:10.1155/2018/9182747] [PMID] [PMCID]
60. Gonzalez-Villoria AM, Valverde-Garduno V. Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen. J Pathog. 2016;2016:7318075. [DOI:10.1155/2016/7318075] [PMID] [PMCID]
61. Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL, et al. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019;79:179-84. [DOI:10.1016/j.ijid.2018.11.371] [PMID]
62. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292-301. [DOI:10.1111/2049-632X.12125] [PMID]
63. Willems S, Kampmeier S, Bletz S, Kossow A, Köck R, Kipp F, et al. Whole-genome sequencing elucidates epidemiology of nosocomial clusters of Acinetobacter baumannii. J Clin Microbiol. 2016;54(9),2391-4. [DOI:10.1128/JCM.00721-16] [PMID] [PMCID]
64. Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3(3):243-50. [DOI:10.4161/viru.19700] [PMID] [PMCID]
65. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012;39(2):105-14. [DOI:10.1016/j.ijantimicag.2011.10.004] [PMID]
66. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-8. [DOI:10.1128/AAC.50.1.43-48.2006] [PMID] [PMCID]
67. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):441-51. [DOI:10.1586/erp.10.49] [PMID] [PMCID]
68. Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant pseudomonas infections: hard to treat, but hope on the horizon?. Curr Infect Dis Rep. 2018;20(8):23. [DOI:10.1007/s11908-018-0629-6] [PMID]
69. Dou Y, Huan J, Guo F, Zhou Z, Shi Y. Pseudomonas aeruginosa prevalence, antibiotic resistance and antimicrobial use in Chinese burn wards from 2007 to 2014. J Int Med Res. 2017;45(3):1124-37. [DOI:10.1177/0300060517703573] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Iranian Journal of Medical Microbiology by Farname is licensed under CC BY-NC 4.0
